In addition to disease modelling, stratification, and screening, Organ-on-a-Chip technology is predicted to be useful for many other applications.

 

Organ-on-a-chip

Organ-on-a-chip technology is gaining traction against the backdrop of regulatory restrictions on animal testing and increasing complexity in therapeutic applications. Several businesses are attempting to capitalise on potential growth possibilities in the market for organ-on-a-chip technologies. It is a one-of-a-kind cell culture procedure that employs a biomimetic microsystem as a platform.

These devices are made of silicone, which has the potential to be utilised to create internal organs. This is useful in organ transplantation as well as treatments. The Wyss Institute at Harvard University is developing lung-on-chip technology, the commercialization of which would aid in the exponential expansion of the organ-on-a-chip business. Furthermore, collaborations between biotech and pharmaceutical businesses and universities are projected to accelerate the commercialization process in the near future. This multibillion-dollar sector is projected to provide several market possibilities for participants. Some firms, such as Mimetas, are now working on kidney-on-a-chip technology. This method is gaining popularity since it significantly minimises the quantity of animal testing while producing very precise findings.

Organ-on-a-chip technology is predicted to be useful for a wide range of applications, including disease modelling, patient stratification, and phenotypic screening. The majority of demand is projected to come from lung-based organ culture, followed by kidney application. When compared to petri dishes and animal testing, the technology provides superior clinical exams, allowing scientists and corporations to better comprehend the functioning of internal organs such as the brain and lungs.

Organs-on-chips (OoCs) are microfluidic chips that contain artificial or natural tiny tissues. The chips are meant to manage cell microenvironments and retain tissue-specific functionalities in order to better resemble human physiology. OoCs have received interest as a next-generation experimental platform to research human pathophysiology and the effect of medicines in the body, combining breakthroughs in tissue engineering and microfabrication. Because there are as many instances of OoCs as there are applications, it can be difficult for novice researchers to comprehend what makes one OoC better suited to a certain application than another.

Despite their simplicity in comparison to actual tissues and organs, scientists have shown that these systems may frequently function as good mimics of human physiology and illness. OoCs are sophisticated in vitro technologies that allow for the study of biological cells and tissues outside of the body. This is accomplished by enclosing them in containers that have been conditioned to maintain a decent resemblance of the in vivo environment, both biochemically and physically. Working on the microscale provides a unique chance to gain more control over the milieu that assures tissue life support, as well as the ability to directly watch cell and tissue behaviour.